Neurobo Pharmaceuticals Inc
NASDAQ:NRBO
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.65
6.52
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one NRBO stock under the Base Case scenario is 3.4 USD. Compared to the current market price of 2.65 USD, Neurobo Pharmaceuticals Inc is Undervalued by 22%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Neurobo Pharmaceuticals Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for NRBO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Neurobo Pharmaceuticals Inc
Balance Sheet Decomposition
Neurobo Pharmaceuticals Inc
Current Assets | 28.5m |
Cash & Short-Term Investments | 27.9m |
Other Current Assets | 583k |
Non-Current Assets | 234k |
PP&E | 213k |
Other Non-Current Assets | 21k |
Current Liabilities | 9.7m |
Accounts Payable | 2.6m |
Accrued Liabilities | 2.6m |
Other Current Liabilities | 4.5m |
Non-Current Liabilities | 98k |
Other Non-Current Liabilities | 98k |
Earnings Waterfall
Neurobo Pharmaceuticals Inc
Revenue
|
0
USD
|
Operating Expenses
|
-26.5m
USD
|
Operating Income
|
-26.5m
USD
|
Other Expenses
|
621k
USD
|
Net Income
|
-25.9m
USD
|
Free Cash Flow Analysis
Neurobo Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
NRBO Profitability Score
Profitability Due Diligence
Neurobo Pharmaceuticals Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Score
Neurobo Pharmaceuticals Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
NRBO Solvency Score
Solvency Due Diligence
Neurobo Pharmaceuticals Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Score
Neurobo Pharmaceuticals Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NRBO Price Targets Summary
Neurobo Pharmaceuticals Inc
Dividends
Current shareholder yield for NRBO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
NRBO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. The company is headquartered in Boston, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2016-08-05. The firm is engaged in the development and commercialization of therapeutics. The company is focused on four therapeutics programs designed to impact a range of indications in viral, neurodegenerative and cardiometabolic disease. The Company’s therapeutics programs include ANA001, NB-01, NB-02 and Gemcabene. Its ANA001, is an oral niclosamide formulation and was developed as a treatment for patients with moderate coronavirus disease (COVID-19). NB-01, which is primarily focused on the development of a treatment for painful diabetic neuropathy and treat a range of neuropathic conditions. Its NB-02, which treats the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of a protein called tau, and with amyloid beta plaque deposition. The Company’s Gemcabene, which is being assessed as an acute indication for COVID-19 treatments.
Contact
IPO
Employees
Officers
The intrinsic value of one NRBO stock under the Base Case scenario is 3.4 USD.
Compared to the current market price of 2.65 USD, Neurobo Pharmaceuticals Inc is Undervalued by 22%.